Jocasta Neuroscience

About Jocasta Neuroscience

Jocasta Neuroscience, Inc. is a preclinical-stage biotechnology company developing therapeutics to address cognitive decline in neurodegenerative diseases. Founded in 2021 and headquartered in Scottsdale, Arizona, the company's lead program focuses on a proprietary formulation of the α-Klotho protein, a circulating factor associated with longevity and improved cognitive function in preclinical studies. This foundational technology was originally developed at the University of California, San Francisco (UCSF) by Dr. Dena Dubal and was licensed to Jocasta after further development by Unity Biotechnology.

The company's lead asset, JN-0413, is being developed to manage cognitive decline associated with various forms of dementia. Preclinical data has demonstrated α-Klotho's role in health and its potential for cognitive enhancement, supporting the advancement of JN-0413 into human trials. Jocasta is led by CEO Dr. Albert Agro, who has extensive experience in drug development and has led multiple biotech companies through IPOs and acquisitions. The founding team also includes Dr. Michael Davidson and Dr. Dena Dubal, who collaborate to advance the company's proprietary formulation through clinical development.

In August 2025, Jocasta Neuroscience announced it had secured $35 million in a Series A financing round. The round was led by True Ventures, with participation from Moore Strategic Ventures, SC8 Investments, Glentura, and the Yagan Family Foundation. The funds are intended to support the development of JN-0413 through Phase 1 clinical studies, with a planned Investigational New Drug (IND) submission in late 2026.